Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Oct 28, 2024
Date Accepted: Jun 19, 2025

The final, peer-reviewed published version of this preprint can be found here:

Sustained Virological Response as a Surrogate Marker for Mortality, Decompensated Cirrhosis, or Hepatocellular Carcinoma in People With Chronic Hepatitis C Virus Infection Treated With Direct-Acting Antivirals: Protocol for a Bayesian and Causal Mediation Analysis

Gurusamy KS, Gluud C

Sustained Virological Response as a Surrogate Marker for Mortality, Decompensated Cirrhosis, or Hepatocellular Carcinoma in People With Chronic Hepatitis C Virus Infection Treated With Direct-Acting Antivirals: Protocol for a Bayesian and Causal Mediation Analysis

JMIR Res Protoc 2025;14:e68113

DOI: 10.2196/68113

PMID: 40633094

PMCID: 12287667

Protocol for evaluation of sustained virological response as a surrogate marker for mortality, decompensated cirrhosis, or hepatocellular carcinoma in people with chronic hepatitis C virus infection treated with direct-acting antivirals: Bayesian and causal mediation analyses

  • Kurinchi Selvan Gurusamy; 
  • Christian Gluud

ABSTRACT

Background:

Sustained virological response (SVR) is commonly used as an indicator of treatment success in people with chronic hepatitis C virus (HCV) infection. However, there is uncertainty on whether SVR is a validated surrogate marker of successful treatment of chronic HCV infection.

Objective:

The aim of this research project is to evaluate whether SVR is a good surrogate for all-cause mortality, decompensated cirrhosis, or any specific aspect of liver decompensation (jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal haemorrhage), or hepatocellular carcinoma in people with chronic HCV infection eligible to receive direct-acting antiviral drugs.

Methods:

Data source Two ongoing systematic reviews on the effectiveness of direct-acting antiviral drugs in chronic HCV infection. Analysis 1. Estimate the regression coefficients or between-studies correlation between SVR and the event by three different Bayesian approaches with OpenBUGS, as outlined in the guidance by the Evidence Synthesis Unit (Technical support document 20). 2. Estimate the average proportion of the effect mediated through SVR by causal mediation analysis using R.

Results:

As on 14 May 2025, the two systematic reviews on the effectiveness of direct-acting antiviral drugs in chronic HCV infection are ongoing.

Conclusions:

We will use the German Institute of Quality and Efficiency in Health Care (IQWiG) criterion for surrogacy for cancer and at least 50% of the treatment effect mediated through SVR but will report the information in a way that allows people to interpret the information using their own criteria. Clinical Trial: Not applicable


 Citation

Please cite as:

Gurusamy KS, Gluud C

Sustained Virological Response as a Surrogate Marker for Mortality, Decompensated Cirrhosis, or Hepatocellular Carcinoma in People With Chronic Hepatitis C Virus Infection Treated With Direct-Acting Antivirals: Protocol for a Bayesian and Causal Mediation Analysis

JMIR Res Protoc 2025;14:e68113

DOI: 10.2196/68113

PMID: 40633094

PMCID: 12287667

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.